Why targeting HDL should work as a therapeutic tool, but has not

Journal of Cardiovascular Pharmacology

Volumn 62, Issue 3, 2013, Pages 239-246

  Sorci Thomas, Mary G ^a   Thomas, Michael J ^b  

^a Lipid Sciences Research Center   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoprotein A I; Atherosclerosis; Cardiovascular disease; Cholesterol efflux; Cholesterol transport; High density lipoprotein; Inflammation; Lipid raft; Nascent HDL

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL TRANSPORT; DISABILITY; DRUG TARGETING; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CHOLESTEROL; DRUG RESISTANCE; HUMANS; HYPOALPHALIPOPROTEINEMIAS; LIPID REGULATING AGENTS; LIPOPROTEINS, HDL; LIVER; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY;

EID: 84884671413     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31829d48a5     Document Type: Review

References (159)

1. Kwiterovich PO. The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol. 1998;82:13Q-21Q
2. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: Assessing the data from Framingham to the Veterans affairs high-density lipoprotein intervention trial. Am J Cardiol. 2000;86:19L-22L
3. Harper CR, Jacobson TA. New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med. 1999; 159:1049-1057
4. Libby P. What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol. 2001;88:3J-6J
5. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000
6. Yancey PG, Bortnick AE, Kellner-Weibel G, et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003;23:712-719
7. Libby P. Managing the risk of atherosclerosis: The role of high-density lipoprotein. Am J Cardiol. 2001;88:3N-8N
8. Rader DJ, Tall AR. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18:1344-1346
9. Mestas J, Ley K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med. 2008;18:228-232
10. Kennedy MA, Barrera GC, Nakamura K, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 2005;1:121-131
11. Trigatti BL, Rigotti A, Braun A. Cellular and physiological roles of SR-BI, a lipoprotein receptor which mediates selective lipid uptake. Biochim Biophys Acta. 2000;1529:276-286
12. Trigatti B, Rigotti A, Krieger M. The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism. Curr Opin Lipidol. 2000;11:123-131
13. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267
14. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357: 2109-2122
15. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial. JAMA. 2011;306:2099-2109
16. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 367:2089-2099
17. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363: 2406-2415
18. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135
19. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751-2756
20. Sorci-Thomas MG, Zabalawi M, Bharadwaj MS, et al. Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice. Biochim Biophys Acta. 2012;1821:502-512
21. Liu Y, Tang C. Regulation of ABCA1 functions by signaling pathways. Biochim Biophys Acta. 2012;1821:522-529
22. Durrington P. HDL in risk prediction and its direct and indirect involvement in atherogenesis. Atheroscler Suppl. 2002;3:3-12
23. Robbie L, Libby P. Inflammation and atherothrombosis. Ann N Y Acad Sci. 2001;947:167-179; discussion 179-180
24. Steinberg D. Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002;8:1211-1217
25. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002;252:283-294
26. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1. J Lipid Res. 2000;41:1481-1494
27. Shah PK, Kaul S, Nilsson J, et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: An idea whose time for testing is coming, part I. Circulation. 2001;104:2376-2383
28. Zabalawi M, Bharadwaj M, Horton H, et al. Inflammation and skin cholesterol in LDLr-/-, apoA-I-/- mice: Link between cholesterol homeostasis and self-tolerance? J Lipid Res. 2007;48:52-65
29. Murphy AJ, Woollard KJ, Hoang A, et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol. 2008;28:2071-2077
30. Ansell BJ, Navab M, Watson KE, et al. Anti-inflammatory properties of HDL. Rev Endocr Metab Disord. 2004;5:351-358
31. Ingersoll MA, Platt AM, Potteaux S, et al. Monocyte trafficking in acute and chronic inflammation. Trends Immunol. 2011;32:470-477
32. Combadiere C, Potteaux S, Rodero M, et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation. 2008;117:1649-1657
33. Yvan-Charvet L, Welch C, Pagler TA, et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: Free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation. 2008;118: 1837-1847
34. Yvan-Charvet L, Ranalletta M, Wang N, et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest. 2007;117:3900-3908
35. Moore RE, Navab M, Millar JS, et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res. 2005;97:763-771
36. Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res. 2004;95:764-772
37. Parthasarathy S, Wieland E, Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci U S A 1989;86:1046-1050
38. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481-488
39. Potteaux S, Gautier EL, Hutchison SB, et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J Clin Invest. 2011;121:2025-2036
40. Wan W, Murphy PM. Regulation of atherogenesis by chemokines and chemokine receptors. Arch Immunol Ther Exp (Warsz). 2013;61:1-14
41. Weber C, Noels H. Atherosclerosis: Current pathogenesis and therapeutic options. Nat Med. 2011;17:1410-1422
42. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol. 2011;31: 1506-1516
43. Jones KL, Maguire JJ, Davenport AP. Chemokine receptor CCR5: From AIDS to atherosclerosis. Br J Pharmacol. 2011;162:1453-1469
44. Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol. 2010;30:139-143
45. Bursill CA, Castro ML, Beattie DT, et al. High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2010;30:1773-1778
46. Tang C, Liu Y, Kessler PS, et al. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem. 2009; 284:32336-32343
47. Wilhelm AJ, Zabalawi M, Grayson JM, et al. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol. 2009;29:843-849
48. Wilhelm AJ, Zabalawi M, Owen JS, et al. Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/- mice. J Biol Chem. 2010;285:36158-36169
49. Fraga J, Garcia-Diez A. Lupus erythematosus panniculitis. Dermatol Clin. 2008;26:453-463, vi.
50. Park HS, Choi JW, Kim BK, et al. Lupus erythematosus panniculitis: Clinicopathological, immunophenotypic, and molecular studies. Am J Dermatopathol. 2010;32:24-30
51. Zabalawi M, Bhat S, Loughlin T, et al. Induction of fatal inflammation in LDL receptor and ApoA-I double-knockout mice fed dietary fat and cholesterol. Am J Pathol. 2003;163:1201-1213
52. van der Vorst EP, Vanags LZ, Dunn LL, et al. High-density lipoproteins suppress chemokine expression and proliferation in human vascular smooth muscle cells. FASEB J. 2013;27:1413-1425
53. Zhu X, Parks JS. New roles of HDL in inflammation and hematopoiesis. Annu Rev Nutr. 2012;32:161-182
54. Hamon Y, Broccardo C, Chambenoit O, et al. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat Cell Biol. 2000;2:399-406
55. Su YR, Ishiguro H, Major AS, et al. Macrophage apolipoprotein A-I expression protects against atherosclerosis in ApoE-deficient mice and up-regulates ABC transporters. Mol Ther. 2003;8:576-583
56. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30:796-801
57. Mulya A, Lee JY, Gebre AK, et al. Minimal lipidation of pre-beta HDL by ABCA1 results in reduced ability to interact with ABCA1. Arterioscler Thromb Vasc Biol. 2007;27:1828-1836
58. Mulya A, Lee JY, Gebre AK, et al. Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL. J Lipid Res. 2008;49:2390-2401
59. Cuchel M, Lund-Katz S, de la Llera-Moya M, et al. Pathways by which reconstituted high-density lipoprotein mobilizes free cholesterol from whole body and from macrophages. Arterioscler Thromb Vasc Biol. 2010;30:526-532
60. Rye KA, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 2004;24: 421-428
61. Sorci-Thomas MG, Owen JS, Fulp B, et al. Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. J Lipid Res. 2012;53:1890-1909
62. Sorci-Thomas MG, Thomas MJ. High density lipoprotein biogenesis, cholesterol efflux, and immune cell function. Arterioscler Thromb Vasc Biol. 2012;32:2561-2565
63. Mitchell CD, King WC, Applegate KR, et al. Characterization of apolipoprotein E-rich high density lipoproteins in familial lecithin:cholesterol acyltransferase deficiency. J Lipid Res. 1980;21:625-634
64. Norum KA, Glomset JA, Nichols AV, et al. Plasma lipoproteins in familial lecithin:cholesterol acyltransferase deficiency: Effects of incubation with lecithin:cholesterol acyltransferase in vitro. Scand J Clin Lab Invest Suppl. 1975;35(suppl 42):31-55
65. Kontush A, Therond P, Zerrad A, et al. Preferential sphingosine-1- phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: Relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol. 2007;27:1843-1849
66. Pike LJ, Han X, Gross RW. Epidermal growth factor receptors are localized to lipid rafts that contain a balance of inner and outer leaflet lipids: A shotgun lipidomics study. J Biol Chem. 2005;280:26796-26804
67. Brown DA, Rose JK. Sorting of GPI-anchored proteins to glycolipidenriched membrane subdomains during transport to the apical cell surface. Cell. 1992;68:533-544
68. Rosenson RS, Brewer HB Jr, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 2011;57:392-410
69. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1:31-39
70. Zech T, Ejsing CS, Gaus K, et al. Accumulation of raft lipids in T-cell plasma membrane domains engaged in TCR signalling. EMBO J. 2009; 28:466-476
71. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science. 2010;327:46-50
72. Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117:185-194
73. Barlic J, Murphy PM. Chemokine regulation of atherosclerosis. J Leukoc Biol. 2007;82:226-236
74. Subramanian M, Thorp E, Hansson GK, et al. Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J Clin Invest. 2013; 123:179-188
75. Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Potential implications for acute plaque stabilization. Circulation. 2001;103: 3047-3050
76. Fisher EA, Feig JE, Hewing B, et al. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012;32:2813-2820
77. Eriksson M, Carlson LA, Miettinen TA, et al. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation. 1999; 100:594-598
78. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA. 2003;290:2292-2300
79. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of reconstituted highdensity lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA. 2007;297:1675-1682
80. Nanjee MN, Doran JE, Lerch PG, et al. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol. 1999;19:979-989
81. Nanjee MN, Cooke CJ, Garvin R, et al. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res. 2001;42:1586-1593
82. Nieuwdorp M, Vergeer M, Bisoendial RJ, et al. Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. Diabetologia. 2008;51:1081-1084
83. Shaw JA, Bobik A, Murphy A, et al. Infusion of reconstituted highdensity lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res. 2008;103:1084-1091
84. Patel S, Drew BG, Nakhla S, et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J AmColl Cardiol. 2009;53:962-971
85. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-167
86. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228
87. Rosenson RS, Brewer HB Jr, Davidson WS, et al. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905-1919
88. Timmins JM, Lee JY, Boudyguina E, et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest. 2005;115:1333-1342
89. Nichols AV, Blanche PJ, Gong EL, et al. Molecular pathways in the transformation of model discoidal lipoprotein complexes induced by lecithin-cholesterol acyltransferase. Biochim Biophys Acta. 1985;834: 285-300
90. Liang HQ, Rye KA, Barter PJ. Remodelling of reconstituted high density lipoproteins by lecithin:cholesterol acyltransferase. J Lipid Res. 1996;37:1962-1970
91. Woollett LA, Kearney DM, Spady DK. Diet modification alters plasma HDL cholesterol concentrations but not the transport of HDL cholesteryl esters to the liver in the hamster. J Lipid Res. 1997;38:2289-2302
92. Woollett LA, Spady DK. Kinetic parameters for high density lipoprotein apoprotein AI and cholesteryl ester transport in the hamster. J Clin Invest. 1997;99:1704-1713
93. Spady DK, Woollett LA, Meidell RS, et al. Kinetic characteristics and regulation of HDL cholesteryl ester and apolipoprotein transport in the apoA-I-/- mouse. J Lipid Res. 1998;39:1483-1492
94. Alam K, Meidell RS, Spady DK. Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. J Biol Chem. 2001;276:15641-15649
95. Zhang Y, Zanotti I, Reilly MP, et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003;108:661-663
96. Martel C, Li W, Fulp B, et al. Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J Clin Invest. 2013;123: 1571-1579
97. Davidson WS, Silva RA, Chantepie S, et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters. Relevance to antioxidative function. Arterioscler Thromb Vasc Biol. 2009; 29:870-876
98. Heinecke JW. The protein cargo of HDL: Implications for vascular wall biology and therapeutics. J Clin Lipidol. 2010;4:371-375
99. Vickers KC, Remaley AT. Functional diversity of HDL cargo. J Lipid Res. 2013
100. Heinecke JW. HDL's protein cargo: Friend or foe in cardioprotection? Circulation. 2013;127:868-869
101. Navab M, Reddy ST, Van Lenten BJ, et al. The role of dysfunctional HDL in atherosclerosis. J Lipid Res. 2009;50(suppl):S145-S149
102. Nicholls SJ, Hazen SL. Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res. 2009;50(suppl):S346-S351
103. Navab M, Reddy ST, Van Lenten BJ, et al. HDL and cardiovascular disease: Atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8:222-232
104. Shao B, Heinecke JW. HDL, lipid peroxidation, and atherosclerosis. J Lipid Res. 2009;50:599-601
105. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121:2693-2708
106. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117:746-756
107. Green PS, Vaisar T, Pennathur S, et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation. 2008;118:1259-1267
108. Tselepis AD, Dentan C, Karabina SA, et al. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocytederived enzyme. Arterioscler Thromb Vasc Biol. 1995;15:1764-1773
109. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol. 2007;18:427-434
110. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13:423-433
111. Davalos A, Goedeke L, Smibert P, et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A 2011;108:9232-9237
112. Regazzi R, Widmann C. Genetics and molecular biology: MiRNAs take the HDL ride. Curr Opin Lipidol. 2012;23:165-166
113. Navab M, Ananthramaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. J Lipid Res. 2004;45:993-1007
114. Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A 1992;89:10316-10320
115. Hadfield KA, Pattison DI, Brown BE, et al. Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional highdensity lipoproteins: Comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCl). Biochem J. 2013;449:531-542
116. Shao B, Oda MN, Oram JF, et al. Myeloperoxidase: An oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol. 2010;23:447-454
117. Maceyka M, Harikumar KB, Milstien S, et al. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22:50-60
118. Hla T, Dannenberg AJ. Sphingolipid signaling in metabolic disorders. Cell Metab. 2012;16:420-434
119. Wilkerson BA, Grass GD, Wing SB, et al. Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: High density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1. J Biol Chem. 2012;287:44645-44653
120. Argraves KM, Argraves WS. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J Lipid Res. 2007;48: 2325-2333
121. Xu N, Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem. 1999;274:31286-31290
122. Christoffersen C, Obinata H, Kumaraswamy SB, et al. Endotheliumprotective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A 2011;108:9613-9618
123. Karuna R, Park R, Othman A, et al. Plasma levels of sphingosine-1- phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis. 2011;219:855-863
124. Arkensteijn BW, Berbee JF, Rensen PC, et al. The apolipoprotein m-sphingosine-1-phosphate axis: Biological relevance in lipoprotein metabolism, lipid disorders and atherosclerosis. Int J Mol Sci. 2013; 14:4419-4431
125. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002; 296:346-349
126. Brinkmann V, DavisMD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277:21453- 21457
127. Argraves KM, Sethi AA, Gazzolo PJ, et al. S1P, dihydro-S1P and C24: 1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 2011;10:70
128. Sattler KJ, Elbasan S, Keul P, et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol. 2010;105:821-832
129. Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of highdensity lipoprotein effects in cardiovascular protection. Cardiovasc Res. 2009;82:201-211
130. Keul P, Lucke S, von Wnuck Lipinski K, et al. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res. 2011;108:314-323
131. Camerer E, Regard JB, Cornelissen I, et al. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest. 2009;119:1871-1879
132. Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol. 2012;30:69-94
133. Bolick DT, Srinivasan S, Kim KW, et al. Sphingosine-1-phosphate prevents tumor necrosis factor-{alpha}-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler Thromb Vasc Biol. 2005; 25:976-981
134. Poti F, Bot M, Costa S, et al. Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptordeficient (LDL-R(-/-)) mice. Thromb Haemost. 2012;107:552-561
135. Hughes JE, Srinivasan S, Lynch KR, et al. Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ Res. 2008; 102:950-958
136. Skoura A, Michaud J, Im DS, et al. Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:81-85
137. Obinata H, Hla T. Sphingosine 1-phosphate in coagulation and inflammation. Semin Immunopathol. 2012;34:73-91
138. Xia P, Wadham C. Sphingosine 1-phosphate, a key mediator of the cytokine network: Juxtacrine signaling. Cytokine Growth Factor Rev. 2011;22:45-53
139. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009;27:165-197
140. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007;117:195-205
141. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in lowdensity lipoprotein receptor-deficient mice. Circulation. 2007;115: 501-508
142. Klingenberg R, Nofer JR, Rudling M, et al. Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2007; 27:2392-2399
143. Poti F, Costa S, Bergonzini V, et al. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R(-)/(-)) mice. Vascul Pharmacol. 2012;57:56-64
144. Keul P, Tolle M, Lucke S, et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:607-613
145. Wang SH, Yuan SG, Peng DQ, et al. High-density lipoprotein affects antigen presentation by interfering with lipid raft: A promising antiatherogenic strategy. Clin Exp Immunol. 2010;160:137-142
146. Wang SH, Yuan SG, Peng DQ, et al. HDL and ApoA-I inhibit antigen presentation-mediated T cell activation by disrupting lipid rafts in antigen presenting cells. Atherosclerosis. 2012;225:105-114
147. Norata GD, Pirillo A, Ammirati E, et al. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis. 2012; 220:11-21
148. Cheng AM, Handa P, Tateya S, et al. Apolipoprotein A-I attenuates palmitate-mediated NF-kappaB activation by reducing Toll-like receptor-4 recruitment into lipid rafts. PLoS One. 2012;7:e33917
149. Zhu X, Owen JS, Wilson MD, et al. Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J Lipid Res. 2010;51:3196-3206
150. Zhu X, Lee JY, Timmins JM, et al. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem. 2008;283:22930-22941
151. Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997; 387:569-572
152. Popik W, Alce TM, Au WC. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J Virol. 2002;76:4709-4722
153. Carter GC, Bernstone L, Sangani D, et al. HIV entry in macrophages is dependent on intact lipid rafts. Virology. 2009;386:192-202
154. Kamiyama H, Yoshii H, Tanaka Y, et al. Raft localization of CXCR4 is primarily required for X4-tropic human immunodeficiency virus type 1 infection. Virology. 2009;386:23-31
155. Zhukovsky MA, Lee PH, Ott A, et al. Putative cholesterol-binding sites in human immunodeficiency virus (HIV) coreceptors CXCR4 and CCR5. Proteins. 2013;81:555-567
156. Singleton PA, Dudek SM, Ma SF, et al. Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family. J Biol Chem. 2006;281: 34381-34393
157. Rye KA, Clay MA, Barter PJ. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis. 1999;145:227-238
158. Kee P, Rye KA, Taylor JL, et al. Metabolism of apoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: Studies in wild-type and hepatic lipase transgenic rabbits. Arterioscler Thromb Vasc Biol. 2002;22:1912-1917
159. Heinecke JW. The not-so-simple HDL story: A new era for quantifying HDL and cardiovascular risk? Nat Med. 2012;18:1346-1347